Media

Race Oncology Ltd executive director and chairman Dr Peter Smith talked with Proactive about securing more than A$3.22 million via a private placement to fund the HARNESS-1 Phase 1a/b clinical trial. Read full article here.

Special Report: Racura Oncology has taken a significant step forward in the clinical development of its next-generation cancer therapy RC220, receiving human ethics approval for a HARNESS-1 Phase 1a/b trial in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Read full article here.

Special Report: Racura Oncology has discovered the unique molecular mechanism of action for its RC220 therapy, opening two new major potential indications to explore in a clinical setting. Read full article here.

Proactive Investors covered Racura Oncology’s cardio-oncology strategy and the potential of RC220 to make anthracycline-based chemotherapy safer for patients. The article highlights progress in our international Phase 1 trial, our dual anticancer and cardioprotective approach, and recent IP advances supporting long-term value creation. Read the full article here.

Stockhead and The Australian included Racura Oncology in an ASX healthcare company quarterly results season wrap up, which highlights ongoing progress, including new discoveries and clinical trial updates to propel growth in FY26. The article covers Racura’s progress on clinical trials and the company’s discovery of a new way of patenting active chemical form of…

Racura Oncology CEO Dr Daniel Tillett spoke to Stockhead’s Tylah Tully to discuss the groundbreaking discovery of the primary mechanism of action of their lead drug. Dr Tillett explains how understanding the drug’s mechanism increases the probability of clinical success, allowing Racura to identify the cancer types most likely to respond, develop predictive biomarkers, and design…

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector and selects Racura Oncology as his ‘Powerplay’ stock pick of the week. Read the full article here.

Racura Oncology has uncovered a fresh chapter in its lead cancer program, identifying a novel mechanism of action for its (E,E)-bisantrene candidate. New data shows the compound binds to G4-DNA and RNA structures — genetic “switches” that regulate cancer-driving genes like MYC — setting it apart from doxorubicin-like chemotherapies that remain the backbone of treatment…

Racura Oncology CEO Dr Daniel Tillett spoke to Stockhead’s Tylah Tully about the company’s major scientific discovery, which has enabled a new composition of matter patent application for the (E,E)-bisantrene compound.  Dr Tillett explains why composition of matter patents are considered the gold standard in biotech IP, critical for securing future licensing and acquisition interest from…